GeoVax Labs, Inc. (GOVX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, GeoVax Labs reported revenue of $2.5M, down 37.1% from $4.0M the year before. Net income was -$21.5M (a -862.3% net margin). Operating margin was -869.3%. Operating activities generated -$21.5M of cash, leaving -$21.5M of free cash flow. At fiscal year end, GeoVax Labs held $6.3M in total assets against $2.5M in total liabilities, including $3.1M of cash and equivalents.
Open the full interactive GeoVax Labs financials → Quarterly statements, key ratios, valuation history and price charts.
GeoVax Labs Key Stats
| Share Price | $0.27 |
|---|---|
| Market Cap | $1.2M |
| Revenue YoY Growth | -37.1% |
| 52-Week Range | $0.27 – $15.10 |
| Shares Outstanding | 4.6 million (basic, 2026 Q2) |
GeoVax Labs Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $385,501 | $81,526 | $0 | $4.0M | $2.5M |
| Operating Income | -$2.8M | -$18.7M | -$14.0M | -$26.7M | -$25.1M | -$21.6M |
| Pre-Tax Income | -$3.0M | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| Income Tax | $0 | $0 | — | — | — | — |
| Net Income | -$3.0M | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| Diluted EPS | -$802.50 | -$1140.00 | — | — | — | — |
GeoVax Labs Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$6.3M | -$4.4M | -$5.3M | -$4.4M |
GeoVax Labs Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.9M | $11.4M | $27.6M | $6.5M | $5.5M | $3.1M |
| Current Assets | $10.2M | $11.6M | $28.9M | $7.9M | $7.9M | $5.3M |
| Total Assets | $10.4M | $11.8M | $31.3M | $9.3M | $8.2M | $6.3M |
| Current Liabilities | $810,309 | $5.4M | $4.7M | $3.5M | $3.1M | $1.9M |
| Total Long-Term Debt | $198,064 | — | — | — | — | — |
| Total Liabilities | $825,047 | $7.4M | $4.7M | $3.5M | $3.1M | $2.5M |
| Shareholders' Equity | $9.6M | $4.4M | $26.6M | $5.8M | $5.0M | $3.8M |
GeoVax Labs Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$2.8M | -$11.2M | -$19.0M | -$25.2M | -$24.7M | -$21.5M |
| Cash From Investing | -$156,791 | -$47,718 | -$134,258 | -$48,946 | -$20,653 | -$27,612 |
| Cash From Financing | $12.5M | $12.8M | $35.4M | $4.1M | $23.8M | $19.1M |
| Free Cash Flow | -$2.9M | -$11.2M | -$19.2M | -$25.2M | -$24.7M | -$21.5M |
Figures from GeoVax Labs' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full GeoVax Labs financials page for every line item.
GeoVax Labs Company Profile
| Ticker | GOVX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Smyrna, Georgia |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000832489 |
Frequently Asked Questions
What was GeoVax Labs' revenue in fiscal 2025?
GeoVax Labs (GOVX) reported revenue of $2.5M for fiscal 2025.
What is GeoVax Labs' annual revenue history?
GeoVax Labs' annual revenue by fiscal year: 2020: $1.8M; 2021: $385,501; 2022: $81,526; 2023: $0; 2024: $4.0M; 2025: $2.5M.
What was GeoVax Labs' net income in fiscal 2025?
GeoVax Labs reported net income of -$21.5M for fiscal 2025.
How much free cash flow did GeoVax Labs generate in fiscal 2025?
GeoVax Labs generated -$21.5M of free cash flow in fiscal 2025.
What was GeoVax Labs' revenue last quarter?
In its most recent reported quarter (2026 Q2), GeoVax Labs reported revenue of $0.
How many shares of GeoVax Labs are outstanding?
GeoVax Labs reported a weighted average of 4.6 million basic shares outstanding in 2026 Q2.
What is GeoVax Labs' market cap?
Based on its latest closing price, GeoVax Labs (GOVX) has a market capitalization of about $1.2M.
When does GeoVax Labs' fiscal year end?
GeoVax Labs' fiscal year end, as registered with the SEC, is December 31.
Where is GeoVax Labs headquartered?
GeoVax Labs lists its business address in Smyrna, Georgia in its SEC filings.